Skip to content

Author

Salomon Manier

We have 3 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.

Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al. · 0 citations
Open access Sep 2026

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma

An NF-κB-associated inflammatory axis underlying poor DR response is underscores an NF-κB-associated inflammatory axis underlying poor DR response and suggests that targeting inflammatory pathways a potential therapeutic avenue warranting further investigation.

Wen-Wen Cheng, S. Gaggero, Lama Hasan Bou Issa et al. · 0 citations
Open access Sep 2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...

I. Dekhtiarenko, Jan Attig, I. Lelios et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.